Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 7/20 | 0.63 |
| ▸ | NPC1 | O15118 | 6/20 | 0.63 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.61 |
| ▸ | LMNA | P02545 | 3/20 | 0.61 |
| ▸ | RECQL | P46063 | 1/20 | 0.61 |
| ▸ | HTT | P42858 | 1/20 | 0.60 |
| ▸ | PRMT5 | O14744 | 4/20 | 0.60 |
| ▸ | WDR77 | Q9BQA1 | 4/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.58 |
| ▸ | MEN1 | O00255 | 2/20 | 0.58 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.52 |
| ▸ | NFKB2 | Q00653 | 2/20 | 0.52 |
| ▸ | RELA | Q04206 | 2/20 | 0.52 |
| ▸ | HPGD | P15428 | 2/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | TP53 | P04637 | 1/20 | 0.49 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.48 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.48 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5477242 | 0.90 | RAB9A (0.73) | RAB9ANPC1SMN1; SMN2LMNARECQL | |
| Water SCHEMBL6484487 | 0.80 | SMN1; SMN2 (0.77) | RAB9ANPC1SMN1; SMN2LMNAHTT | |
| Water SCHEMBL6484483 | 0.80 | SMN1; SMN2 (0.77) | RAB9ANPC1SMN1; SMN2LMNAHTT | |
| SCHEMBL5479816 | 0.80 | RAB9A (0.62) | RAB9ANPC1SMN1; SMN2LMNARECQL | |
| SCHEMBL6484650 | 0.79 | NPC1 (0.61) | RAB9ANPC1SMN1; SMN2LMNAHTT | |
| SCHEMBL5485409 | 0.77 | RAB9A (0.56) | RAB9ANPC1SMN1; SMN2LMNARECQL | |
| SCHEMBL5475685 | 0.77 | RAB9A (0.59) | RAB9ANPC1SMN1; SMN2LMNARECQL | |
| SCHEMBL5478987 | 0.77 | RAB9A (0.64) | RAB9ANPC1SMN1; SMN2LMNARECQL | |
| SCHEMBL6482646 | 0.77 | PRMT5 (0.43) | RAB9ANPC1SMN1; SMN2LMNARECQL | |
| SCHEMBL5472719 | 0.76 | PRMT5 (0.54) | RAB9ANPC1SMN1; SMN2LMNARECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6974836-B2 | Diamines as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2005-12-13 | — | — | US | claimed |
| US-6906078-B2 | Method of using (H+/K+) ATPase inhibitors as antiviral agents | PHARMACIA CORPORATION (US) | 2005-06-14 | — | — | US | disclosed |
| US-20010047038-A1 | Method of using (H+/K+) ATPase inhibitors as antiviral agents | MOORMAN ALAN E (US) | 2001-11-29 | — | — | US | disclosed |
| WO-1995029897-A1 | METHOD OF USING (H+/K+) ATPase INHIBITORS AS ANTIVIRAL AGENTS | G.D. SEARLE & CO. (US) | 1995-11-09 | — | — | WO | disclosed |
| EP-0204215-A1 | 2-[(1H-benzimidazol-2-ylsulfinyl)methyl]-benzenamines | G.D. Searle & Co. (US) | 1986-12-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010047038-A1 | Method of using (H+/K+) ATPase inhibitors as antiviral agents | ATP4A, ATP1A1, ATP1A4 | RAB9A 486/4885NPC1 363/4885SMN1; SMN2 4616/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.